{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000444","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.199173+00:00","generated_at":"2026-06-20T18:15:16.406643+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Rani Therapeutics enters license/supply deal with Celltrion for oral ustekinumab biosimilar","bullets":["Rani obtains exclusive worldwide royalty-free license to Celltrion's ustekinumab biosimilar for oral delivery using Rani's platform.","Celltrion will supply the biosimilar; Rani must purchase exclusively from Celltrion unless supply disruption.","Celltrion has right of first negotiation for commercialization after Phase 1 data package; 30-day exercise, 90-day negotiation.","Rani owns all data from research and development; can terminate for convenience; Celltrion can terminate if milestones not met."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000444","json":"https://secwatch.observer/filing/0000950170-23-000444.json","markdown":"https://secwatch.observer/filing/0000950170-23-000444.md","text":"https://secwatch.observer/filing/0000950170-23-000444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023000444/0000950170-23-000444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023000444/rani-20230106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:15:16.406643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"36740c9e0821ca61873c10ae0a2534170d72aa12","claim":"Rani Therapeutics Holdings, Inc. entered into License Agreement with Celltrion, Inc. (effective 2023-01-06).","evidence_excerpt":"On January 6, 2023, Rani Therapeutics, LLC, an operating subsidiary of Rani Therapeutics Holdings, Inc. (“Rani”), and Celltrion, Inc. (“Celltrion”) entered into a License and Supply Agreement (the “License Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1856725/000095017023000444/0000950170-23-000444-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Celltrion, Inc."},{"label":"Effective","value":"2023-01-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}